NEWS & MEDIA

Archive: 2021

Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna
February 12, 2021 — FOR IMMEDIATE RELEASE - The U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD) have purchased an additional 100 million doses of COVID-19 vaccines from both Pfizer Inc. and Moderna Inc. to help meet demand for COVID-19 vaccines in the United States.The orders placed today bring the vaccine purchased by the U.S...

DOD Awards Industry Partner Immunome $13.3 Million for Biosynthetic Convalescent Plasma Development
February 11, 2021 — The JPM CBRN Medical leveraged an industry partnership to accelerate COVID-19 prevention and treatment research...

DOD Awards $231.8 Million Contract to Ellume USA LLC to Increase Domestic Production Capacity and Deliver COVID-19 Home Tests
February 1, 2021 — FOR IMMEDIATE RELEASE - On Feb. 1, 2021, the Department of Defense (DOD), in coordination with the Department of Health and Human Services, awarded $231.8 million to Ellume USA LLC to onshore production capacity of the Ellume COVID-19 Home Test for the United States.This industrial base expansion effort will allow Ellume USA LLC to increase...

DOD Supports Phase III Clinical Trial Using Fostamatinib (TAVALISSE®) Against COVID-19
January 29, 2021 — The JPM CBRN Medical executed an agreement with Rigel Pharmaceuticals, Inc., to study the effectiveness of TAVALISSE® against COVID-19...

DOD Supports Phase II Clinical Trials Repurposing Inhaled PUL-042 for COVID-19 Prevention and Treatment
January 26, 2021 — The JPM CBRN Medical executed an agreement with Pulmotect, Inc. to study the effectiveness of an existing compound that shows promise against COVID-19...

Increased Collaboration Promotes Improved Medical Diagnostic Capabilities and Health Outcomes
January 25, 2021 — The U.S. Department of Defense (DOD) has a long-standing history of developing medical countermeasures (MCMs) to combat deadly biological threats. Vaccines, diagnostics, and therapeutics serve in a fully-layered continuum of defense capabilities that both protect before exposure as well as to inform and treat after exposure. This set of...

HHS, DOD purchase additional doses of Regeneron therapeutic to treat patients with mild to moderate COVID-19
January 12, 2021 — The Department of Health and Human Services (HHS) and the Department of Defense (DOD) today announced the purchase of 1.25 million additional treatment courses of Regeneron’s investigational monoclonal antibody therapeutic, a combination of casirivimab and imdevimab, to be delivered in the first half of 2021 to treat non-hospitalized, high-risk...

News Search

News Archive - Search by Year and Month

CPE CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the CPE CBRND's Capabilities Catalog, Leadership Biographies, and contracting overview documents.

CPE CBRND Public Affairs Office

The CPE CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the CPE CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.

The information contained in these articles has been reviewed and approved for public release.

The appearance of hyperlinks does not constitute endorsement by the CPE CBRND of non-U.S. government sites or the information, products, or services contained therein. Although the CPE CBRND may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all the information that you may find at these locations. Such hyperlinks are provided consistent with the stated purpose of this website.